| NCT06568692 | A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer | RECRUITING | PHASE2 | 2024-10-02 | 2026-10 | 2026-09 |
| NCT05270460 | Safety, PK and Efficacy of PCS12852 on Gastric Emptying Rate in Patients With Moderate to Severe Gastroparesis | COMPLETED | PHASE2 | 2022-03-09 | 2022-10-06 | 2022-09-29 |
| NCT04861987 | A Study of the Safety and PK of PCS6422 (Eniluracil) with Capecitabine in Patients with Advanced, Refractory GI Tract Tumors | COMPLETED | PHASE1 | 2021-06-18 | 2024-09-09 | 2024-06-12 |
| NCT04800562 | A Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica | TERMINATED | PHASE2 | 2021-04-12 | 2023-04-14 | 2023-02-28 |
| NCT03698864 | A Study to Evaluate the Safety and Tolerability of PCS499 for the Treatment of Necrobiosis Lipoidica | COMPLETED | PHASE2 | 2018-11-07 | 2020-02-25 | 2020-02-25 |
| NCT03836222 | Study to Evaluate the PK of Single and Optional Multiple Dosing Regimens of MR Formulations of PCS499 Compared to Trental® Administered to Healthy Subjects | COMPLETED | PHASE1 | 2018-02-26 | 2018-06-04 | 2018-06-04 |
| NCT03189914 | RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer | COMPLETED | PHASE1, PHASE2 | 2017-10-02 | 2019-11-21 | 2019-10-01 |
| NCT02030067 | Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies | COMPLETED | PHASE1, PHASE2 | 2013-12 | 2019-12 | 2019-07 |
| NCT01978366 | Open Label Extension Study of HT-100 in Patients With DMD | TERMINATED | PHASE2 | 2013-10 | 2016-04-30 | 2016-04-30 |
| NCT01847573 | Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of HT-100 in Duchenne Muscular Dystrophy | TERMINATED | PHASE1, PHASE2 | 2013-05 | 2016-03-30 | 2016-03-30 |